CLAIMS

What is claimed is:

1. A compound of Formula (I'):



(I'), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein:

X_1 is N or CR_3;

X_2 is N, N(O), or CR_5;

X_7 is N and N(O);

R_1 is H, D, $-C(O)R_{11}$, $-CH_2OC(O)R_{11}$, $-CH_2OC(O)NHR_{12}$, $-CH_2OC(O)OR_{12}$, $-P(O)(OR_{12})_2$, $-CH_2OP(O)(OR_{12})_2$, $-CH_2OP(O)(OH)OR_{12}$, $-CH_2OP(O)(R_{12})_2$, $-CH_2OC(O)CH_2NHC(O)CH_2NH_2$, $-CH_2OC(O)CH(R_{12'})NHR_{12'}$, $-CH_2OC(O)(CH_2)_q-C(O)OR_{12'}$, or $-CH_2OC(O)$-(5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from O, N, NH, and S);

R_{2a}, R_{2b}, R_{2c}, and R_{2d} are each independently H, D, $(C_1$-$C_6)$alkyl, $(C_1$-$C_6)$deuteroalkyl, halogen, or -OH, wherein two of R_{2a}, R_{2b}, R_{2c}, and R_{2d} may be taken together with the carbon atom to which they are attached to form a $(C_3$-$C_7)$carbocyclyl or $(C_3$-$C_7)$spirocarbocyclyl optionally substituted with one or more R_{40};

R_3 is H, D, $(C_1$-$C_6)$alkyl, $(C_1$-$C_6)$deuteroalkyl, or halogen, wherein R_3 may be taken together with one of R_{2a}, R_{2b}, R_{2c}, and R_{2d} with the carbon atom to which they are attached to form a $(C_3$-$C_7)$carbocyclyl or $(C_3$-$C_7)$spirocarbocyclyl optionally substituted with one or more R_{40};

R_4 is D, $(C_1$-$C_6)$alkyl, $(C_1$-$C_6)$deuteroalkyl, $(C_1$-$C_6)$haloalkyl, $(C_1$-$C_6)$alkoxy, $(C_1$-$C_6)$deuteroalkoxy, $(C_1$-$C_6)$haloalkoxy, $(C_3$-$C_7)$carbocyclyl, $-O(C_3$-$C_7)$carbocyclyl, 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from O, N, NH, and S; halogen, -OH, or $-NR_9R_{10}$; wherein each alkyl, deuteroalkyl, haloalkyl, alkoxy, deuteoalkoxy, haloalkoxy, carbocyclyl, and heterocyclyl is optionally substituted with one or more R_{40};

R_5 is H, D, $(C_1$-$C_6)$alkyl, $(C_1$-$C_6)$deuteroalkyl, $(C_1$-$C_6)$haloalkyl, $(C_1$-$C_6)$alkoxy, $(C_1$-$C_6)$deuteroalkoxy, $(C_1$-$C_6)$haloalkoxy, $(C_3$-$C_7)$carbocyclyl, $O(C_3$-$C_7)$carbocyclyl, $(C_3$-$C_7)$carbocyclyl, 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from O, N, NH, and S; halogen, -OH, or

-NR_9R_{10}, wherein each alkyl, deuteroalkyl, haloalkyl, alkoxy, deuteoalkoxy, haloalkoxy, carbocyclyl, and heterocyclyl is optionally substituted with one or more R_{40};

R_6 is H, D, (C_1-C_6)hydroxyalkyl, (C_1-C_6)halohydroxyalkyl, (C_1-C_6)aminoalkyl, (C_1-C_6)alkyl-O-(C_1-C_6)hydroxyalkyl, -$C(O)R_{11}$, -$CH_2OC(O)R_{11}$, -$CH_2OC(O)NHR_{12}$, -$CH_2OC(O)OR_{12}$, -$P(O)(OR_{12})_2$, -$CH_2OP(O)(OH)OR_{12}$, or -$CH_2OP(O)(R_{12})_2$;

R_{7a}, R_{7b}, R_{7c}, and R_{7d} are each independently H, D, (C_1-C_6)alkyl, (C_1-C_6)deuteroalkyl, or (C_1-C_2)haloalkyl; or

two of R_{7a}, R_{7b}, R_{7c}, and R_{7d} are taken together with the carbon atoms to which they are attached to form (C_3-C_7)carbocyclyl, (C_3-C_7)spirocarbocyclyl, or a 4- to 7-membered spiroheterocyclyl comprising 1 to 4 heteroatoms selected from O, N, NH, and S, wherein the carbocyclyl, spirocarbocyclyl and spiroheterocyclyl are optionally substituted with one or more substituents independently selected from D, (C_1-C_6)alkyl, (C_1-C_6)deuteroalkyl, (C_1-C_6)haloalkyl, (C_1-C_6)alkoxy, (C_1-C_6)haloalkoxy, (C_1-C_6)hydroxyalkyl, halogen, -$C(O)OR_{13'}$, -$C(O)R_{13}$, and -$C(O)NR_{13'}R_{13'}$;

each R_{7e} is independently at each occurrence D, (C_1-C_6)alkyl, (C_1-C_6)deuteroalkyl, (C_1-C_6)haloalkyl, (C_1-C_6)alkoxy, (C_1-C_6)haloalkoxy, halogen, (C_1-C_6)hydroxyalkyl, -CN, -OH, -O-(C_1-C_6)hydroxyalkyl, (C_6-C_{10}) aryl, 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from O, N, NH, and S, (C_3-C_7)carbocyclyl, or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from O, N, NH, and S, wherein the alkyl is optionally substituted with one or more R_{19}, the aryl and heteroaryl are optionally substituted with one or more R_{21}, and the carbocyclyl and heterocyclyl are optionally substituted with one or more R_{22}; or

two R_{7e} together with the carbon atom to which they are attached form a (C_3-C_7)carbocyclyl, (C_3-C_7)spirocarbocyclyl, or a 4- to 7-membered spiroheterocyclyl comprising 1 to 4 heteroatoms selected from O, N, NH, and S, wherein the carbocyclyl, spirocarbocyclyl and spiroheterocyclyl are optionally substituted with one or more substituents independently selected from D, (C_1-C_6)alkyl, (C_1-C_6)deuteroalkyl, (C_1-C_6)haloalkyl, (C_1-C_6)alkoxy, (C_1-C_6)haloalkoxy, (C_1-C_6)hydroxyalkyl, halogen, -$C(O)OR_{13'}$, -$C(O)R_{13}$, and -$C(O)NR_{13'}R_{13'}$;

one R_{7e} is taken together with any one of R_{7a}, R_{7b}, R_{7c}, and R_{7d} and the atoms to which they are attached to form a (C_3-C_7)carbocyclyl or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from O, N, NH, and S, wherein the carbocyclyl and heterocyclyl are optionally substituted with one or more R_{22};

R_8 is (C_1-C_6)alkyl, (C_1-C_6)haloalkyl, (C_1-C_6)hydroxyalkyl, (C_1-C_6)halohydroxyalkyl, or (C_3-C_7)carbocyclyl, wherein alkyl, haloalkyl, hydroxyalkyl, halohydroxyalkyl, and carbocyclyl are optionally substituted with one or more substituents independently selected from R_{21}, D, (C_1-C_6)alkoxy, -SF_5, -SR_{14a}, -$NR_{14}R_{14'}$, -$C(O)NR_{32}R_{33}$, phenyl, 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected

from O, N, NH, and S, (C_3-C_7)carbocyclyl, or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from O, N, NH, and S, wherein the phenyl and heteroaryl are optionally substituted with one or more R_{15} and the carbocyclyl and heterocyclyl are optionally substituted with one or more $R_{15'}$;

R_9 and R_{10} are each independently at each occurrence H, D, (C_1-C_6)alkyl, (C_1-C_6)deuteroalkyl, or (C_1-C_6)haloalkyl;

R_{11} is independently at each occurrence H, (C_1-C_6)alkoxy, -NH_2, -N(H)(C_1-C_6)alkyl, -N((C_1-C_6)alkyl)$_2$, (C_1-C_6)alkyl optionally substituted with one or more substituents independently selected from (C_6-C_{10})aryl, (C_1-C_6)alkoxy, (C_1-C_6)hydroxyalkyl, (C_1-C_6)haloalkyl, halogen, -OH, -NH_2, and -CN, or (C_6-C_{10})aryl optionally substituted with one or more substituents independently selected from (C_1-C_6)alkyl, (C_1-C_6)alkoxy, (C_1-C_6)hydroxyalkyl, (C_1-C_6)haloalkyl, halogen, -OH, -NH_2, and -CN;

R_{12} is independently at each occurrence H, (C_1-C_6)alkyl optionally substituted with one or more substituents independently selected from (C_6-C_{10})aryl, (C_1-C_6)alkoxy, (C_1-C_6)hydroxyalkyl, (C_1-C_6)haloalkyl, halogen, -OH, -NH_2, and -CN, or (C_6-C_{10})aryl optionally substituted with one or more substituents independently selected from (C_1-C_6)alkyl, (C_1-C_6)alkoxy, (C_1-C_6)hydroxyalkyl, (C_1-C_6)haloalkyl, halogen, -OH, -NH_2, and -CN;

$R_{12'}$ is independently at each occurrence H or (C_1-C_6)alkyl; R_{13} is independently at each occurrence (C_1-C_6)alkyl or (C_1-C_6)haloalkyl;

$R_{13'}$ is independently at each occurrence H, (C_1-C_6)alkyl, or (C_1-C_6)haloalkyl;

R_{14} and $R_{14'}$ are each independently at each occurrence H or (C_1-C_6)alkyl;

R_{14a} is H, (C_1-C_6)alkyl, or (C_1-C_6)haloalkyl;

R_{15} and $R_{15'}$ are each independently at each occurrence D, (C_1-C_6)alkyl, (C_1-C_6)deuteroalkyl, (C_1-C_6)haloalkyl, (C_1-C_6)alkoxy, (C_1-C_6)haloalkoxy, (C_1-C_6)hydroxyalkyl, halogen, -OH, -$NR_{30}R_{31}$, -SF_5, -SR_{16}, -CN, -C(O)$NR_{32}R_{33}$, -C(O)OR_{32}, (C_3-C_7)carbocyclyl, -O(C_3-C_7)carbocyclyl, phenyl, -O-phenyl, monocyclic or bicyclic 5- to 10-membered heteroaryl comprising 1 to 4 heteroatoms selected from O, N, NH, and S, -O-(monocyclic or bicyclic 5- to 10-membered heteroaryl comprising 1 to 4 heteroatoms selected from O, N, NH, and S), 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from O, N, NH, and S or -O-(4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from O, N, NH, and S), wherein alkyl, deuteroalkyl, haloalkyl, alkoxy, haloalkoxy, hydroalkyl, phenyl, heteroaryl, carbocyclyl, and heterocyclyl are optionally substituted with one or more substituents selected from (C_1-C_6)alkyl, (C_1-C_6)haloalkyl, (C_1-C_6)alkoxy, (C_1-C_6)haloalkoxy, (C_1-C_6)hydroxyalkyl, halogen, –OH, -$NR_{35}R_{36}$, -C(O)$NR_{37}R_{38}$, -C(O)R_{37}, -C(O)OR_{37}, -SF_5, -SR_{29}, $SO_2NR_{30}R_{31}$, -CN, and R_{19}; or

two R_{15}, when on adjacent atoms, together with the atoms to which they are attached form a phenyl, 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from O, N, NH, and S, (C_3-C_7)carbocyclyl, or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from O, N, NH,

and S, wherein the phenyl, heteroaryl, carbocyclyl, and heterocyclyl are optionally substituted with one or more R_{17};

two $R_{15'}$, when on adjacent atoms, together with the atoms to which they are attached form a phenyl or 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from O, N, NH, and S, wherein the phenyl and heteroaryl are optionally substituted with one or more R_{17}; or

two $R_{15'}$ together with the atoms to which they are attached form a (C_3-C_7)carbocyclyl or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from O, N, NH, and S, wherein the carbocyclyl and heterocyclyl are optionally substituted with one or more R_{17}; or

two $R_{15'}$ when on the same carbon atom form C=(O);

R_{16} is H, (C_1-C_6)alkyl or (C_1-C_6)haloalkyl;

R_{17} is independently at each occurrence D, (C_1-C_6)alkyl, (C_1-C_6)deuteroalkyl, (C_1-C_6)haloalkyl, (C_1-C_6)alkoxy, (C_1-C_6)haloalkoxy, (C_1-C_6)hydroxyalkyl, halogen, -OH, -NH_2, -SF_5, -SR_{18}, or -CN;

R_{18} is H, (C_1-C_6)alkyl, or (C_1-C_6)haloalkyl;

each R_{19} is independently at each occurrence (C_1-C_6)alkoxy, (C_1-C_6)haloalkoxy, -$NR_{20}R_{20'}$, -CN, (C_3-C_7)carbocyclyl, 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from O, N, NH, and S, (C_6-C_{10}) aryl, or monocyclic or bicyclic 5- to 10-membered heteroaryl comprising 1 to 4 heteroatoms selected from O, N, NH, and S, wherein the carbocyclyl and heterocyclyl are optionally substituted with one or more R_{23} and the aryl and heteroaryl are optionally substituted with one or more R_{24}; or

two R_{19} when on the same carbon atom form C=(O); or

two R_{19} together with the atoms to which they are attached form a (C_3-C_7)carbocyclyl or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from O, N, NH, and S, wherein the carbocyclyl and heterocyclyl are optionally substituted with one or more R_{17};

R_{20} and $R_{20'}$ are each independently at each occurrence H or (C_1-C_6)alkyl;

each R_{21} is independently at each occurrence (C_1-C_6)alkyl, (C_1-C_6)haloalkyl, (C_1-C_6)alkoxy, (C_1-C_6)haloalkoxy, (C_1-C_6)hydroxyalkyl, halogen, -OH, -NH_2, -SF_5, -SR_{25}, -CN, phenyl, 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from O, N, NH, and S, (C_3-C_7)carbocyclyl, or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from O, N, NH, and S; or

two R_{21}, when on adjacent atoms, together with the atoms to which they are attached form a phenyl or 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from O, N, NH, and S, wherein the phenyl and heteroaryl are optionally substituted with one or more R_{15};

each R_{22} is independently at each occurrence (C_1-C_6)alkyl, (C_1-C_6)haloalkyl, (C_1-C_6)alkoxy, (C_1-C_6)haloalkoxy, (C_1-C_6)hydroxyalkyl, halogen, -OH, -NH_2, -SF_5, -SR_{26}, -CN, phenyl, 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from O, N, NH, and S, (C_3-C_7)carbocyclyl, or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from O, N, NH, and S; or

two R_{22} together with the atoms to which they are attached form a (C_3-C_7)carbocyclyl or a 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from O, N, NH, and S;

each R_{23} is independently at each occurrence D, (C_1-C_6)alkyl, (C_1-C_6)haloalkyl, (C_1-C_6)alkoxy, (C_1-C_6)haloalkoxy, (C_1-C_6)hydroxyalkyl, halogen, -OH, -NH_2, -SF_5, -SR_{27}, -CN, phenyl, 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from O, N, NH, and S, (C_3-C_7)carbocyclyl, or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from O, N, NH, and S; or

two R_{23} together with the atoms to which they are attached form a (C_3-C_7)carbocyclyl or a 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from O, N, NH, and S;

each R_{24} is independently at each occurrence D, (C_1-C_6)alkyl, (C_1-C_6)haloalkyl, (C_1-C_6)alkoxy, (C_1-C_6)haloalkoxy, (C_1-C_6)hydroxyalkyl, halogen, -OH, -NH_2, -SF_5, -SR_{28}, -CN, phenyl, 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from O, N, NH, and S, (C_3-C_7)carbocyclyl, or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from O, N, NH, and S;

R_{25}, R_{26}, R_{27}, R_{28}, and R_{29} are each independently at each occurrence H, (C_1-C_6)alkyl, or (C_1-C_6)haloalkyl; R_{30} and R_{31} are each independently at each occurrence H, (C_1-C_6)alkyl, (C_1-C_6)haloalkyl, (C_3-C_7)carbocyclyl, -C(O)R_{34}, phenyl, or 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from O, N, NH, and S, wherein the phenyl or heteroaryl can be substituted with one or more R_{17};

R_{32}, R_{33}, and R_{34} are each independently at each occurrence H or (C_1-C_6)alkyl;

R_{35} and R_{36} are each independently at each occurrence H, (C_1-C_6)alkyl, or -C(O)R_{39};

R_{37}, R_{38}, and R_{39} are each independently at each occurrence H or (C_1-C_6)alkyl;

R_{40} is D, (C_1-C_6)alkyl, (C_1-C_6)deuteroalkyl, (C_1-C_6)haloalkyl, (C_1-C_6)alkoxy, (C_1-C_6)haloalkoxy, (C_1-C_6)hydroxyalkyl, halogen, -OH, -$NR_{30}R_{31}$, -SR_{16}, -CN, -C(O)$NR_{32}R_{33}$, -C(O)OR_{32}, (C_3-C_7)carbocyclyl, -O(C_3-C_7)carbocyclyl, phenyl;

m and n are each independently 0, 1 or 2;

o is 0, 1 or 2;

p is 0, 1, 2, 3 or 4;

q is 1, 2, or 3; and

r is 0 or 1.

2. The compound according to claim 1, wherein;

(i) R_1 is H;

(ii) each of R_{2a}, R_{2b}, R_{2c}, R_{2d} is independently H;

(iii) each of R_{2a}, R_{2b}, R_{2c}, and R_{2d} is independently CH_3;

(iv) X_1 is CR_3;

(v) X_1 is N;

(vi) X_2 is CR_5;

(vii) X_2 is N;

(viii) R_3 is H;

(ix) R_3 is D;

(x) R_3 is CH_3;

(xi) R_4 is independently in each instance (C_1-C_6)alkyl, (C_1-C_6)haloalkyl, -OH, -O-(C_1-C_6)alkyl, -NR_9R_{10}, or halogen;

(xii) R_5 is independently in each instance (C_1-C_6)alkyl, (C_3-C_7)carbocyclyl, -OH, -O-(C_1-C_6)alkyl, -NR_9R_{10}, or halogen;

(xiii) n is 0;

(xiv) n is 1;

(xv) m is 0;

(xvi) m is 1; and/or

(xvii) m is 2.

3. The compound according to claim 1, wherein;

(i) R_6 is H;

(ii) R_{7a} is H or (C_1-C_6)alkyl;

(iii) R_{7b} is H;

(iv) R_{7c} is H; and/or

(v) R_{7d} is H.

4. The compound according to claim 1, wherein each R_{7e} is independently at each occurrence , , , , , , , , or ; or

two R_{7e}, when on the same carbon atom, together with the carbon atom to which they are attached, form , , , , , or , wherein

R in each instance is independently selected from D, (C_1-C_6)alkyl, (C_1-C_6)deuteroalkyl, (C_1-C_6)haloalkyl, (C_1-C_6)alkoxy, (C_1-C_6)haloalkoxy, (C_1-C_6)hydroxyalkyl, halogen, -C(O)$OR_{13'}$, -C(O)R_{13}, and -C(O)$NR_{13'}R_{13'}$; and

R_{21}, R_{22}, and R_{24} are defined as in claim 1.

5. The compound according to claim 1, wherein;

(i) o is 2;

(ii) o is 1;

(iii) p is 0;

(iv) p is 1;

(v) p is 2; and/or

(vi) p is 4.

6. The compound according to claim 1, having a Formula (Ia), Formula (Ib), Formula (Ic), Formula (Id), Formula (Ie), Formula (If), Formula (Ig), Formula (Ih), Formula (Ii), Formula (Ij), Formula (Ik), or Formula (Il):


(Ia),


(Ib),


(Ic),


(Id),


(Ie),


(If),


(Ig),

(Ih),

(Ii),

(Ij),

(Ik), or

(Il),

or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

7. The compound according to claim 1, having a Formula (Im), Formula (Io), Formula (Ip), Formula (Iq), Formula (Ir), Formula (Iu), Formula (Iv), Formula (Iw), Formula (Ix), Formula (Iy), Formula (Iz), Formula (Iaa), Formula (Ibb), or Formula (Icc):


(Im),

(Io),

(Ip),

(Iq),


(Ir),

(Iu),

(Iv),

(Iw),

(Ix),

(Iy),

(Iz),

(Iaa),

(Ibb), or

(Icc).

8. The compound according to claim 1, wherein R_8 is selected from:



wherein

each of X_{3a} and X_{3b} is independently selected from O, S, NH, and NR_{15};

X_4 is O, S, NH, and $NR_{15'}$;

R is selected from $(C_1\text{-}C_5)$alkyl and $(C_3\text{-}C_7)$cycloalkyl, and is optionally substituted with one or more of D, hydroxy, halogen, alkoxy, imidazol-2-yl, and $-C(O)NR_{32}R_{33}$; and

R_{15}, $R_{15'}$, R_{32}, and R_{33} are as defined in claim 1.

9. The compound according to claim 1, wherein each R_{19} is independently at each occurrence $(C_1\text{-}C_6)$alkoxy, $-NR_{20}R_{20'}$, or $(C_3\text{-}C_7)$carbocyclyl wherein carbocyclyl is optionally substituted with two to four R_{23}.

10. The compound according to claim 1, wherein the compound is selected from any compound provided in Table 1, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

11. A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier or excipient.

12. The pharmaceutical composition according to claim 11, further comprising at least one additional pharmaceutical agent.

13. The pharmaceutical composition according to claim 11 for use in the treatment of a disease or disorder that is affected by the reduction of HIF-1β levels.

14. A compound according to claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof for use in degrading HIF-1β or modulating HIF-1β levels.

15. A compound according to claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in treating a disease or disorder that is affected by the modulation of HIF-1β levels.

16. The compound for use according to claim 15, wherein the disease or disorder is selected from cancer, von Hippel-Lindau (VHL) disease, iron overload disorders, cardiovascular diseases, pulmonary diseases, autoimmune and inflammatory-related diseases and conditions, neurodegenerative diseases, viral diseases, metabolic diseases, neovascular diseases, retinal vascular diseases, fibrosis, endometriosis, preeclampsia, and allergic and genetic diseases.

17. The compound for use according to claim 15, wherein the disease or disorder is selected from renal cell carcinoma (RCC), von Hippel-Lindau disease (VHL), advanced pheochromocytoma/paraganglioma (PPGL), pancreatic neuroendocrine tumor (pNET), pulmonary arterial hypertension (PAH), glioblastoma, colitis, Crohn's disease, ulcerative colitis, T cell leukemia or T cell lymphoma, Hodgkin's lymphoma or non-Hodgkin's lymphoma, non-small cell lung cancer (NSCLC), melanoma, triple-negative breast cancer (TNBC), nasopharyngeal cancer (NPC), microsatellite stable colorectal cancer (mssCRC), thymoma, carcinoid, gastrointestinal stromal tumor (GIST), myeloid leukemia, and coronary heart disease.

18. A compound according to claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in treating a disease or disorder selected from cancer, von Hippel-Lindau (VHL) disease, iron overload disorders, cardiovascular diseases, pulmonary arterial hypertension (PAH), autoimmune and inflammatory-related diseases and conditions, neurodegenerative diseases, viral diseases, metabolic diseases, and allergic and genetic diseases.

19. The compound for use according to claim 18, wherein the disease or disorder is selected from cancer or von Hippel-Lindau (VHL) disease .

20. The compound for use according to claim 18, wherein the cancer is selected from renal cell carcinoma (RCC), glioblastoma, T cell leukemia or T cell lymphoma, Hodgkin's lymphoma or non-Hodgkin's lymphoma, non-small cell lung cancer (NSCLC), melanoma, triple-negative breast cancer (TNBC), nasopharyngeal cancer (NPC), microsatellite stable colorectal cancer (mssCRC), thymoma, carcinoid, gastrointestinal stromal tumor (GIST), and myeloid leukemia.

21. The compound for use of claim 18, wherein the disease or disorder is renal cell carcinoma (RCC).

22. The compound for use of claim 21, wherein the renal cell carcinoma is clear cell renal cell carcinoma (ccRCC).

23. The compound for use according to claim 15 or 18, wherein the administration is oral, parenteral, subcutaneous, by injection, or by infusion.